Krystal Biotech
About company:
Krystal Biotech is developing gene therapies to address skin diseases. Many debilitating skin diseases lack effective treatments. Krystal is solving this by introducing therapeutic genes into patients with skin diseases. To achieve this, Krystal is using their patented gene therapy platform, Skin TARgeted Delivery (STAR-D), that consists of an engineered HSV-1 vector optimized for gene transfer in skin. The engineered HSV-1 vector is replication-defective and non-integrating such that it can penetrate a broad range of skin cells without posing a risk to genome disruption. The therapies are designed to be administered topically allowing direct and repeat delivery of therapeutic genes to the skin. Krystal’s most advanced therapy for Epidermolysis Bullosa is in Phase 3 trials.
Jobs:
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com